Since next generation sequencing technology offers significant benefits compared to single gene testing by reducing costs, time and increasing the sensitivity, it is feasible to screen multiple cancer related genes in EC patients using multigene panels including POLE and POLD1. The gene discussed is POLE; the disease is cancer.